SCHEMBL7264687

SCHEMBL7264687

CC[C@@](Cc1ccc(Nc2nccc3ccncc23)cc1)(Nc1c(N2CCCCC2)c(=O)c1=O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 2/20 0.38
ITGA4 P13612 2/20 0.38
KDM4E B2RXH2 1/20 0.35
TSHR P16473 1/20 0.34
ALOX15 P16050 1/20 0.33
PDE4B Q07343 1/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
CCND2 P30279 1/20 0.33
CCND3 P30281 1/20 0.33
CNR2 P34972 1/20 0.33
STAT6 P42226 1/20 0.32
HPGD P15428 3/20 0.32
ALDH1A1 P00352 2/20 0.32
GAA P10253 1/20 0.32
SYK P43405 3/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7259845 1.00 ITGB1 (0.38) ITGB1ITGA4KDM4ETSHRALOX15
SCHEMBL7259998 0.80 ITGB1 (0.61) ITGB1ITGA4
SCHEMBL7259987 0.80 ITGB1 (0.61) ITGB1ITGA4
SCHEMBL7259521 0.80 ITGB1 (0.61) ITGB1ITGA4
SCHEMBL7259528 0.80 ITGB1 (0.61) ITGB1ITGA4
SCHEMBL3832801 0.79 ITGB1 (0.35) ITGB1ITGA4HDAC3HDAC1HDAC6
SCHEMBL7264675 0.79 ITGB1 (0.41) ITGB1ITGA4KDM4ETSHRALOX15
SCHEMBL7259840 0.79 ITGB1 (0.41) ITGB1ITGA4KDM4ETSHRALOX15
SCHEMBL7260169 0.79 ITGB1 (0.59) ITGB1ITGA4
SCHEMBL7260178 0.79 ITGB1 (0.59) ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545013-B2 Of squaric acids; inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells. CELLTECH R&D LIMITED (GB) 2003-04-08 US disclosed
US-20020115684-A1 2, 7-naphthyridine derivatives CELLTECH R&D, LTD. (GB) 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115684-A1 2, 7-naphthyridine derivatives VCAM1, ICAM1, SELL ITGB1 35/4885ITGA4 267/4885KDM4E 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.